Zimmer Biomet (NYSE:ZBH – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect Zimmer Biomet to post earnings of $2.30 per share and revenue of $2.01 billion for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. During the same period last year, the company earned $1.65 earnings per share. The company’s quarterly revenue was up 4.1% on a year-over-year basis. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.
Zimmer Biomet Trading Down 0.5 %
NYSE ZBH opened at $111.25 on Thursday. The company’s 50 day moving average price is $107.87 and its 200 day moving average price is $108.20. Zimmer Biomet has a one year low of $100.67 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The firm has a market capitalization of $22.15 billion, a price-to-earnings ratio of 21.15, a PEG ratio of 1.88 and a beta of 1.02.
Zimmer Biomet Dividend Announcement
Wall Street Analysts Forecast Growth
ZBH has been the subject of several recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday. Barclays reduced their price objective on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a research note on Thursday, December 12th. Wells Fargo & Company upped their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Finally, Truist Financial increased their price objective on Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and an average target price of $124.11.
Get Our Latest Stock Analysis on Zimmer Biomet
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Read More
- Five stocks we like better than Zimmer Biomet
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Trading Stocks: RSI and Why it’s Useful
- 3 Steel Stocks Soaring After Tariff Announcements
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.